
Release date: 2026-01-06 10:53:20 Article From: Lucius Laos Recommended: 141
Non-small cell lung cancer
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended:[list:visits]2026-30-07
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartinib is an oral tablet.···【more】
Recommended:[list:visits]2026-29-07
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital ···【more】
Recommended:[list:visits]2026-28-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended:[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended:[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended:[list:visits]2026-21-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643